Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 49OTHER 32NIH 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Has results × pertuzumab × Clear all
NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
240 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT03644186 2024-12-13

TOUCH

ETOP IBCSG Partners Foundation

Phase 2 Completed
147 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡